EGFR analysis: Current evidence and future directions

Diagnostic Cytopathology

Volumn 42, Issue 11, 2014, Pages 984-992

  Bellevicine, Claudio ^a   Malapelle, Umberto ^a   De Luca, Caterina ^a   Iaccarino, Antonino ^a   Troncone, Giancarlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aspiration; Cytology; EGFR; Lung cancer; Next generation sequencing

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MOLECULAR MARKER; MONOCLONAL ANTIBODY; TUMOR MARKER; EGFR PROTEIN, HUMAN;

ANALYSIS; CYTOLOGY; ENZYME ANALYSIS; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; IMMUNOCYTOCHEMISTRY; LUNG ADENOCARCINOMA; NEXT GENERATION SEQUENCING; REVIEW; SMEAR; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG NEOPLASMS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE;

CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84912526590     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.23142     Document Type: Review

References (73)

1. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096.
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-1174.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
4. Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: Results from a European workshop. J Thorac Oncol 2010;5:1706-1713.
5. Boldrini L, Gisfredi S, Ursino S, et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: A sensitive method for molecular diagnosis. J Thorac Oncol 2007;2:1086-1090.
6. Savic S, Tapia C, Grilli B, et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of nonsmall-cell lung cancers. Br J Cancer 2008;98:154-160.
7. Clark DP. Seize the opportunity: Underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer Cytopathol 2009;117:289-297.
8. Lozano MD, Zulueta JJ, Echeveste JI, et al. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: Correlation with clinical outcomes. Oncologist 2011;16:877-885.
9. Bozzetti C, Negri FV, Azzoni C, et al. Epidermal growth factor receptor and Kras gene expression: Reliability of mutational analysis on cytological samples. Diagn Cytopathol 2013;41:595-598.
10. Bruno P, Mariotta S, Ricci A, et al. Reliability of direct sequencing of EGFR: Comparison between cytological and histological samples from the same patient. Anticancer Res 2011;31:4207-4210.
11. Chowdhuri SR, Xi L, Pham TH, et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol 2012;25:548-555.
12. Goto K, Satouchi M, Ishii G, et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 2012;23:2914-2919.
13. Mitiushkina NV, Iyevleva AG, Poltoratskiy AN, et al. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol 2013;121:370-376.
14. Sun PL, Jin Y, Kim H, Lee CT, Jheon S, Chung JH. High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas. Cancer Cytopathol 2012;5:21260.
15. Khode R, Larsen DA, Culbreath BC, et al. Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. Cancer Cytopathol 2013;121:361-369.
16. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011;29:2972-2977.
17. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137:828-860.
18. Aisner DL, Deshpande C, Baloch Z, et al. Evaluation of EGFR mutation status in cytology specimens: An institutional experience. Diagn Cytopathol 2013;41:316-323.
19. Allegrini S, Antona J, Mezzapelle R, et al. Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma. Am J Clin Pathol 2012;138:377-381.
20. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: Molecular testing by using cytology specimens. Cancer Cytopathol 2011;119:111-117.
21. Cai G, Wong R, Chhieng D, et al. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol 2013;121:500-507.
22. Pang B, Matthias D, Ong CW, et al. The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: A single South East Asian laboratory's analysis of 670 cases. Cytopathology 2012;23:229-236.
23. Van Eijk R, Licht J, Schrumpf M, et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One 2011;6:e17791.
24. Killian JK, Walker RL, Suuriniemi M, et al. Archival fine-needle aspiration cytopathology (FNAC) samples: Untapped resource for clinical molecular profiling. J Mol Diagn 2010;12:739-745.
25. Malapelle U, Bellevicine C, De Luca C, et al. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non small cell lung cancer patients. Cancer Cytopathol 2013;121:552-560.
26. Knoepp SM, Roh MH. Ancillary techniques on direct-smear aspirate slides: A significant evolution for cytopathology techniques. Cancer Cytopathol 2013;121:120-128.
27. Dejmek A, Zendehrokh N, Tomaszewska M, Edsjo A. Preparation of DNA from cytological material: Effects of fixation, staining, and mounting medium on DNA yield and quality. Cancer Cytopathol 2013;121:344-353.
28. Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol 2011;136:564-571.
29. Da Cunha Santos G, Schroder M, Zhu JB, et al. Minimizing delays in DNA retrieval: The "freezer method" for glass coverslip removal. Letter to the editor regarding comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. Cancer Cytopathol 2013;121:533.
30. Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006;126:608-615.
31. Smith GD, Chadwick BE, Willmore-Payne C, Bentz JS. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol 2008;61:487-493.
32. Aisner DL, Sams SB. The role of cytology specimens in molecular testing of solid tumors: Techniques, limitations, and opportunities. Diagn Cytopathol 2012;40:511-524.
33. Wu HH, Eaton JP, Jones KJ, et al. Utilization of cell-transferred cytologic smears in detection of EGFR and KRAS mutation on adenocarcinoma of lung. Mod Pathol. 2013.. doi:10.1038/modpathol. 2013.220.
34. Malapelle U, De Rosa N, Rocco D, et al. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: A pilot study. J Clin Pathol 2012;65:87-91.
35. Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 2008;3:1224-1235.
36. Roy Chowdhuri S, Hanson J, Cheng J, et al. Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples. Acta Cytol 2012;56:622-631.
37. Brachtel EF, Iafrate AJ, Mark EJ, Deshpande V. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma. Diagn Cytopathol 2007;35:257-262.
38. Marotti JD, Schwab MC, McNulty NJ, et al. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: A retrospective review of 50 cases. Diagn Cytopathol 2013;41:15-21.
39. Esterbrook G, Anathhanam S, Plant PK. Adequacy of endobronchial ultrasound transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer. Lung Cancer 2013;80:30-34.
40. Sanz-Santos J, Serra P, Andreo F, Llatjos M, Castella E, Monso E. Contribution of cell blocks obtained through endobronchial ultrasound-guided transbronchial needle aspiration to the diagnosis of lung cancer. BMC Cancer 2012;12:34.
41. Loukeris K, Vazquez MF, Sica G, et al. Cytological cell blocks: Predictors of squamous cell carcinoma and adenocarcinoma subtypes. Diagn Cytopathol 2012;40:380-387.
42. Aisner DL, Marshall CB. Molecular pathology of non-small cell lung cancer: A practical guide. Am J Clin Pathol 2012;138:332-346.
43. Bellevicine C, Vita GD, Malapelle U, Troncone G. Applications and limitations of oncogene mutation testing in clinical cytopathology. Semin Diagn Pathol 2013;30:284-297.
44. Lee YS, Jin GY, Han YM, Chung MJ, Park HS. Computed tomography-guided transthoracic needle aspiration biopsy of intrapulmonary lesions: Utility of a liquid-based cytopreparatory technique. Acta Cytol 2008;52:665-670.
45. Kawahara A, Taira T, Abe H, et al. Fixation effect of SurePath preservative fluids using epidermal growth factor receptor mutationspecific antibodies for immunocytochemistry. Cancer Cytopathol 2014;122:145-152.
46. Malapelle U, De Rosa N, Bellevicine C, et al. EGFR mutations detection on liquid-based cytology: Is microscopy still necessary? J Clin Pathol 2012;65:561-564.
47. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, Rodriguez Panadero F, Sahn SA. Management of malignant pleural effusions. Eur Respir J 2001;18:402-419.
48. Han HS, Eom DW, Kim JH, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: Discordance in pleural metastases. Clin Lung Cancer 2011;12:380-386.
49. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara KKN. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 2006;95:1390-1395.
50. Soh J, Toyooka S, Aoe K, et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer 2006;119:2353-2358.
51. Idowu MO. Epidermal growth factor receptor in lung cancer: The amazing interplay of molecular testing and cytopathology. Cancer Cytopathol 2013;121:540-543.
52. Thunnissen E, Kerr KM, Herth FJ, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012;76:1-18.
53. Ambrosini-Spaltro A, Campanini N, Bortesi B, et al. EGFR mutation-specific antibodies in pulmonary adenocarcinoma: A comparison with DNA direct sequencing. Appl Immunohistochem Mol Morphol 2012;20:356-362.
54. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010;12:169-176.
55. Kato Y, Peled N, Wynes MW, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: Immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010;5:1551-1558.
56. Kawahara A, Yamamoto C, Nakashima K, et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010;16:3163-3170.
57. Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010;16:3349-3355.
58. Kozu Y, Tsuta K, Kohno T, et al. The usefulness of mutationspecific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer (Amsterdam, Netherlands) 2011;73:45-50.
59. Wu SG, Chang YL, Lin JW, et al. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One 2011;6:e23303.
60. Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009;15:3023-3028.
61. Von Deimling A, Sahm F, Capper D. Mutation specific antibodies: Tool or dinosaur? Oncotarget 2012;3:907-908.
62. Hasanovic A, Ang D, Moreira AL, Zakowski MF. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer (Amsterdam, Netherlands) 2012;77:299-305.
63. Jiang G, Fan C, Zhang X, et al. Ascertaining an Appropriate Diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer. PLoS One 2013;8:e59183.
64. Tsai T-H, Wu S-G, Chang Y-L, et al. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol 2012;7:993-1000.
65. Da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol 2011;6:49-69.
66. Mayo C, Bertran-Alamillo J, Molina-Vila MA, Gimenez-Capitan A, Costa C, Rosell R. Pharmacogenetics of EGFR in lung cancer: Perspectives and clinical applications. Pharmacogenomics 2012;13:789-802.
67. Shames DS, Wistuba, II. The evolving genomic classification of lung cancer. J Pathol 2014;232:121-133.
68. De Biase D, Visani M, Malapelle U, et al. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy). PLoS One 2013;8:e83607.
69. Buttitta F, Felicioni L, Del Grammastro M, et al. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res 2013;19:691-698.
70. Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: Promises and challenges. Cancer Lett 2013;340:284-295.
71. Karnes HE, Duncavage EJ, Bernadt CT. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung. Cancer Cytopathol 2014;122:104-113.
72. Young G, Wang K, Fau He J, et al. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol 2013;121:688-694.
73. Scarpa A, Sikora K, Fassan M, et al. Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One 2013;8:e80478.